索罗克替 | 54063-56-8

• 物质功能分类: 分析化学 - 标准品 - 法医和兽医标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 索罗克替
• 中文别名: 舒洛地尔
• 英文名称: Suloctidil
• 英文别名: 2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol
• CAS: 54063-56-8
• 化学式: C₂₀H₃₅NOS
• 分子量: 337.6
• InChiKey: BFCDFTHTSVTWOG-UHFFFAOYSA-N

物化性质

• 熔点：
  62-63°
• 沸点：
  467.3±35.0 °C(Predicted)
• 密度：
  0.99±0.1 g/cm3(Predicted)
• 碰撞截面：
  197.3 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
• 保留指数：
  2515

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  23
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  57.6
• 氢给体数：
  2
• 氢受体数：
  3

ADMET

毒理性

• 药物性肝损伤

.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotidil.sulcotid

Compound:sulcotidil

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

药物性肝损伤标注：最令人关注的药物性肝损伤

DILI Annotation:Most-DILI-Concern

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

严重程度等级：8

Severity Grade:8

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

标签部分：已撤回

Label Section:Withdrawn

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

参考文献：M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. 美国食品药品监督管理局批准的药物标签用于研究药物诱导的肝损伤，《药物发现今日》，16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank：按人类发展药物诱导肝损伤风险排名的最大参考药物清单。《药物发现今日》2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  索罗克替 、 间氯过氧苯甲酸 生成 2-(octylamino)-1-(4-propan-2-ylsulfinylphenyl)propan-1-ol;hydrochloride
  参考文献：
  名称：

  MORINAKA, YASUXIRO;XATAKEH, SYUNSUKEH;NISI, XIROESI;MORI, MOTOKUNI;KANEHY+

  摘要：

  DOI：

文献信息

• Dibenzyl Amine Compounds and Derivatives
  申请人：Chang George

  公开号：US20070213371A1

  公开（公告）日：2007-09-13

  Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  二苯基胺化合物及其衍生物，含有这种化合物的药物组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物，包括人类。
• [EN] IMIDAZOTRIAZINONE COMPOUNDS<br/>[FR] COMPOSÉS IMIDAZOTRIAZINONES
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2012040230A1

  公开（公告）日：2012-03-29

  The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including CNS or neurodegeneration disorder.

  本发明提供了嘧啶三唑酮类化合物，这些化合物是磷酸二酯酶9的抑制剂。本发明还提供了在治疗哺乳动物中PDE9相关疾病或紊乱，包括中枢神经系统或神经退行性疾病中使用这些化合物的方法、药物组合物、药物制剂和药物用途。
• [EN] TREATMENT OF NEURODEGENERATIVE CONDITIONS<br/>[FR] TRAITEMENT D'ETATS NEURODEGENERATIFS
  申请人：BTG INT LTD

  公开号：WO2005018632A1

  公开（公告）日：2005-03-03

  A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of Ϝ-linolenic acid, dihomo-Ϝ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.

  提供了一种治疗神经退行性疾病患者的方法，包括向该患者施用含有甘油基团和脂肪酸基团的治疗有效剂量的脂质甘油酯，所述脂肪酸基团选自Ϝ-亚麻酸、二油酸和花生四烯酸组成的群体，其特点在于所选的脂肪酸基团附着在甘油基团的sn-2位置。最好的方法是，脂质被施用的持续时间和剂量足以维持或提高患者体内TGF-β1水平至治疗水平。
• BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1422228A1

  公开（公告）日：2004-05-26

  The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

  本发明提供了一种新型的苯并氮杂环衍生物，其由以下公式表示： 其中，R1是一个5-或6-成员的芳香环，R2是低级烷基团等，Y是可选地取代的亚氨基，环A和环B是独立地选自一个可选地取代的芳香环，W是公式-W1-X2-W2-（W1和W2是独立地为S(O)m1（m1是0、1或2）等，X2是一个可选地取代的亚烷基团等），其制备方法及其用途。
• [EN] DIMERIC PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE DIMERES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006008260A1

  公开（公告）日：2006-01-26

  The compounds of the following formula (I) : the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, useful in the treatment of neurodegenerative mediated disorders.

  以下公式（I）的化合物：N-氧化物形式，药用可接受的添加盐及其立体异构形式，在治疗神经退行性媒介紊乱中具有用途。